Physician
Oncology
Dr. Jonathan C. Trent II, MD
|
|
Give Review
Jonathan Trent practices Oncology. He went to medical school at University of Texas Medical School. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Dr. Jonathan C. Trent II is a published MD. He has 58 papers published. The most current publication "Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic." Jonathan C. Trent II, MD accepts Medicare.
Publications
- Managing GIST in the imatinib era: optimization of adjuvant therapy.
- Targeted polytherapy in small Cell sarcoma and its association with doxorubicin.
- Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors.
- Squamous cell carcinoma arising in dedifferentiated chondrosarcoma proved by isocitrate dehydrogenase mutation Analysis.
- Management and outcome of 239 adolescent and adult rhabdomyoSarcoma patients.
- BRAF Mutant Gastrointestinal Stromal Tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for Analysis of acquired...
- Extraskeletal myxoid chondroSarcoma with small bowel metastasis causing bowel obstruction.
- Exploiting antitumor immunity to overcome relapse and improve remission duration.
- PAX3/7-FOXO1 fusion status in older rhabdomyosarcoma patient population by fluorescent in Situ hybridization.
- Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma.
- Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment.
- Adjuvant and neoadjuvant imatinib therapy: Current role in the management of GIST.
- Small-Intestinal Rhabdoid Gastrointestinal Stromal Tumor (GIST): Mutation Analysis and Clinical Implications of a Rare Morphological Variant.
- Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and Malignant solitary fibrous tumor.
- Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ Cancers -- Letter.
- R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis.
- Integrated proteomics and genomics Analysis reveals a novel mesenchymal to epithelial reverting transition in leiomyosarcoma through regulation of slug.
- Response of histiocytoses to imatinib mesylate: fire to ashes.
- Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid Cell tumors.
- Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments.
- Personalized Cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels.
- The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor.
- NCCN Task Force report: update on the management of patients with gastrointestinal stromal Tumors.
- Neoadjuvant treatment of soft-tissue Sarcoma: a multimodality approach.
- Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other Sarcoma patients receiving imatinib mesylate.
- Hepatic arterial embolization and chemoembolization for imatinib-resistant gastrointestinal stromal Tumors.
- Drug plasma monitoring in CML and GIST: A case-based discussion.
- Activity of dasatinib against L576P KIT mutant melanoma: molecular, Cellular, and clinical correlates.
- Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: a series of 5 cases with molecular Analysis.
- A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor Cell apoptosis.
- Clinical update on adult and pediatric gastrointestinal stromal tumor. Preface.
- Toward personalized, targeted therapy of gastrointestinal stromal tumor.
- Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor ...
- Rapid evolution of the biology and treatment of Sarcoma.
- Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.
- Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor.
- Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal Tumors treated with imatinib ...
- Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyoSarcoma: correlation with overall survival in 105 patients.
- Sarcoma molecular testing: diagnosis and prognosis.
- Biomarkers in gastrointestinal stromal tumor: should we equate blood-based pharmacodynamics with tumor biology and clinical outcomes?
- Dasatinib inhibits migration and invasion in diverse human sarcoma Cell lines and induces apoptosis in bone sarcoma Cells dependent on SRC kinase for survival.
- Retroperitoneal soft tissue sarcoma: an Analysis of radiation and surgical treatment.
- Hepatic artery chemoembolization for 110 gastrointestinal stromal Tumors: response, survival, and prognostic factors.
- Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal Tumors treated with imatinib mesylate.
- Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal...
- New developments in gastrointestinal stromal tumor.
- Expression of Bcl-2 in gastrointestinal stromal Tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.
- Gastrointestinal stromal tumor: role of CT in diagnosis and in response evaluation and surveillance after treatment with imatinib.
- Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial Sarcoma.
- Update on the biology and therapy of gastrointestinal stromal Tumors.
- A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal Tumors.
- A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue Sarcomas.
- A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast Cancer.
- Molecular targets in therapy for human soft-tissue and bone Sarcomas.
- Characterization of 11 human sarcoma Cell strains: evaluation of cytogenetics, tumorigenicity, metastasis, and production of angiogenic factors.
- The role of chemotherapy in advanced solitary fibrous tumors: a retrospective Analysis.
- Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Schools
University of Texas At Houston Medical School At Houston
University Tx Med School At Houston
MD Anderson Cancer Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Texas Health Science Center -
University of Texas Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center -
University of Miami Hospital -
Miami Veterans Affairs Healthcare System
Helpful Reviews
Similar Doctors
|
|
Dr. Pasquale W. Benedetto, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos R. Midence Sr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles L. Vogel, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jonathan Cohen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Lisa D. Reale, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mohammad Jahanzeb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gershwin Blyden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn G. Feun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Khaled A. Tolba, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bach Ardalan, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Donald S. Ernst, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Eitan R. Friedman |